Ranbaxy Laboratories, country’s largest drug maker has entered into a licensing agreement with Gilead Sciences to manufacture and market three new HIV/AIDS drugs which are currently in late stage clinical development. Ranbaxy will have the rights to produce and sell generic version of these drugs, under license, in India and other developing nations, after gaining necessary regulatory approvals.
As per the agreement, Ranbaxy will extend its existing relationship with Gilead for anti-retrovirals and have the right to manufacture and market generic equivalent of new products, Elvitegravir, an investigational integrase inhibitor, Cobicistant, an investigational antiretroviral boosting agent and Quad, which combines four Gilead HIV medicines in a ince-daily, single-tablet regimen.
The company posted a net loss from ordinary activities after tax of Rs 52.91 crore for the quarter ended March 31, 2011 as compared to net profit from ordinary activities after tax of Rs 871.80 crore for the corresponding quarter last year. Its total income decreased by 43.25% to Rs 1176.42 crore for the quarter under review from Rs 2073.06 crore in the corresponding previous quarter.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.85 |
Dr. Reddys Lab | 1173.55 |
Cipla | 1525.50 |
Lupin | 2018.35 |
Zydus Lifesciences | 859.10 |
View more.. |